Opinion|Videos|January 13, 2025
Exploring Combination Therapy with Ibrutinib and Rituximab in cGVHD
Author(s)Sergio A. Giralt, MD
Sergio A. Giralt, MD, discusses how rituximab plays a key role in treating chronic graft-vs-host disease. It is often used in combination with ibrutinib to enhance therapeutic outcomes. He reviews the study design and efficacy and safety data from recent trials and discusses how these results will influence his clinical practice moving forward.
Advertisement
Video content above is prompted by the following:
- What is the role of rituximab in your clinical practice in patients with chronic graft-vs-host disease?
- Do you ever use rituximab in combination with ibrutinib?
- What were the study design and methods of this abstract?
- What were the key efficacy and safety results seen in this abstract?
- Will these results impact your clinical practice going forward?
Advertisement
Related to this article
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.
Two inSPire2026 posters detail how health system specialty pharmacy teams support patients with ATTR-CM.
Patients with Sjögren disease diagnosed over a year after symptom onset had 2.3 times the odds of moderate or greater disease activity, a US survey found.
An estimated 44,052 sports eye injuries were treated in 2025 and 1262 pickleball eye injuries in 2024; 99% of lawnmower eye injuries were at home.
Pola-R-GemOx extends median overall survival to 19.5 months in transplant-ineligible R/R DLBCL, per POLARGO.
Teva's Weltruza, a once-monthly subcutaneous olanzapine injection, requires no loading doses, oral supplementation, or postinjection monitoring.
Even when physicians prescribe guideline-preferred therapies, step therapy and prior authorization can delay or restrict access to CLL therapies.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
2
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
3
Bumetanide Nasal Spray Targets Heart Failure Edema Before IV
4
Timing COVID-19 Protection With VYD2311: Michael Mina, MD, PhD
5